Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Operating Leases (2020 - 2026)

PROCEPT BioRobotics has reported Operating Leases over the past 7 years, most recently at $26.3 million for Q1 2026.

  • Quarterly Operating Leases fell 7.0% to $26.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $26.3 million through Mar 2026, down 7.0% year-over-year, with the annual reading at $24.7 million for FY2025, 8.24% down from the prior year.
  • Operating Leases was $26.3 million for Q1 2026 at PROCEPT BioRobotics, up from $24.7 million in the prior quarter.
  • Over five years, Operating Leases peaked at $49.2 million in Q3 2023 and troughed at $829000.0 in Q2 2022.
  • The 5-year median for Operating Leases is $26.3 million (2026), against an average of $25.1 million.
  • Year-over-year, Operating Leases tumbled 53.86% in 2022 and then skyrocketed 3457.18% in 2023.
  • A 5-year view of Operating Leases shows it stood at $22.7 million in 2022, then increased by 15.34% to $26.2 million in 2023, then rose by 2.62% to $26.9 million in 2024, then decreased by 8.24% to $24.7 million in 2025, then increased by 6.81% to $26.3 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Operating Leases are $26.3 million (Q1 2026), $24.7 million (Q4 2025), and $25.2 million (Q3 2025).